1. Introduction
According to the Annual Report of the National Health Research Institutes and Taiwan Society of Nephrology [
1], the prevalence of chronic kidney disease (CKD) and hemodialysis in Taiwan has increased significantly, leading to a rise in health insurance expenditures. This population consists mainly of seniors with multiple chronic diseases. While health management for hemodialysis patients has focused on ensuring their health security, health promotion to prevent comorbidities has received little attention. It is crucial to investigate comorbidities that inordinately affect hemodialysis patients, such as sarcopenia and frailty, be investigated [
2].
Fried et al. [
3] have identified a chain of health problems: CKD, sarcopenia, and frailty. In an aging society like Taiwan’s, CKD and hemodialysis have received community attention and research to reduce their adverse effects. The literature on sarcopenia has focused on its occurrence, primarily within nutrition [
4] and rehabilitation [
5]. However, limited research has addressed the relationship between CKD or hemodialysis and sarcopenia. Preventing a chain reaction of health problems, such as sarcopenia and frailty among CKD hemodialysis patients, requires evaluation and implementation of effective interventions. Accordingly, this study investigated the relationships between sarcopenia, frailty, and related factors in hemodialysis patients with chronic kidney disease.
Frailty, sarcopenia, and CKD are critical determinants of adverse clinical outcomes, including falls, hospitalization, and mortality [
6]. Frailty refers to the body's reduced capacity to withstand health stressors, which can lead to a loss or decline of bodily functions, culminating in multiple functional deficits or adverse health outcomes [
7]. The concept of frailty has derived from biological age and can provide insights into an individual's overall health status. Older individuals are prone to debilitating conditions and have a heightened risk of adverse health outcomes, including falls, extended hospitalization, need for long-term care, and mortality [
6]. Frailty is strongly associated with cardiovascular disease [
8], depression [
9], and quality of life [
10], which highlights the importance of assessing frailty in these conditions.
Fried et al. [
11] have characterized the behavioral performance patterns of frailty, including unintended weight loss, physical exhaustion, low physical activity, slow walking, and muscle weakness. On the other hand, Rockwood and Mitnitski [
12] have characterized the physical multiple impairment pattern of frailty based on sensory, functional, and clinical deficits. These two patterns of frailty interrelate aspects of biology, pathophysiological mechanisms, and clinical features, making it challenging to identify the precise cause of an individual's weak state [
7]. Thus, Rodriguez-Manas et al. [
13] proposed a multidimensional frailty model based on the frailty mechanism and evaluates an individual's actions, cognition and emotions, nutritional status, physical activity, and psychosocial and economic factors. Although the multidimensional frailty model can define an individual's infirmity state, applying it in practical circumstances is challenging. For example, in the above three patterns of frailty, frailty could include insufficient muscle mass and strength. However, when muscle mass and muscle strength are not correlated, an individual's weakness cannot be interpreted [
14].
The concept of sarcopenia originated with Rosenberg [
15], who advocated the exploration of aging and the loss of body muscle mass and functional decline in older people. Age-related sarcopenia is mainly associated with adverse individual health outcomes [
16]. Several groups working on sarcopenia defined it as low skeletal muscle mass and poor muscle strength or physical performance throughout the body or limbs [
17,
18,
19]. The more adverse health factors there are, the higher the likelihood of sarcopenia. For example, decreased muscle strength leads to reduced muscle performance, which can cause impaired mobility, poor health, or higher mortality [
20]. Therefore, physical inactivity is a significant factor in developing sarcopenia [
21], which may be improved by improved nutritional intake [
22].
Sarcopenia is a significant factor in frail patients with CKD. Their pathophysiological changes are associated with age, physical activity, malnutrition, acidosis, metabolic problems, and chronic inflammation [
7]. CKD accelerates the body's protein catabolism, and sarcopenia can impact body functions when insufficient protein intake [
23]. Also, low serum vitamin D and parathyroid hormone concentrations can accentuate sarcopenia in hemodialysis patients [
24]. While sarcopenia is preventable and reversible, timely intervention is crucial to improve muscle mass and strength [
22].
2. Materials and Methods
Study Design and Samples: This prospective cross-sectional study used convenience sampling to recruit participants between August 2021 and February 2022 from a regional hospital affiliated with a hemodialysis center in Southern Taiwan. The hospital had 375 beds, of which 21 were allocated for hemodialysis patients, and operated three daily shifts to service about 117 CKD patients requiring hemodialysis. The inclusion criteria for participants were i) diagnosis of end-stage renal disease; ii) clear consciousness; iii) ability to communicate; and iv) willingness to participate in the study by signing a consent form. Individuals with cognitive impairment, severely weakened states, or critically ill were excluded. The sample size was calculated using G* Power (version 3.1.9.7). A power of 0.8, an alpha of 0.05, and an effect size of 0.3 were used to calculate the sample size. The expected minimum sample size was 71.
Instruments: The study explored the relationship between participants’ characteristics, habits, and health information. The participant characteristics included age, sex, education level, marital status, number of children, living status, number of hospitalizations, falls in the past year, duration of hemodialysis, frequency of hemodialysis per week, and body weight and height. Health information and personal habits were comorbidities, medications, smoking, chewing betel nuts, alcohol consumption, and self-perceived sleep quality. Personal habits were identified through a literature review.
Studies have provided evidence for the relationship between muscle mass and strength and the occurrence of sarcopenia [
25]. In this study, participants' muscle mass and strength were assessed through i) non-dialysis side hand grip strength, measured twice with a one-minute interval using an electronic grip (TTM-YD, Tokyo, Japan). Maximum grip strength values of less than 28 kg for males and less than 18 kg for females were considered indicative of sarcopenia by criteria of the Asian Workshop on Sarcopenia in Older People [
18]. Ii) calf circumference, measured at the fullest part of the calf while the participant was sitting on a chair with both feet on the ground. Calf circumference of less than 34 cm for males and less than 33 cm for females was considered indicative of sarcopenia by the criteria proposed by Shiota et al. [
26]; iii) body mass index (BMI), calculated as body weight (in kg) divided by height (in m2).
The SARC-F, a rapid screening tool designed to measure muscle strength through daily activities [
27], assessed sarcopenia. Each subscale was scored from 0 to 2, with a higher score indicating worse physical function. A total SARC-F score greater than 4 predicted sarcopenia or poor health outcomes. The sensitivity of the SARC-F scale for identifying sarcopenia was 42.9%, and the specificity was 70.8%. The SARC-F has demonstrated internal consistency and validity in detecting sarcopenia [
28].
CFS, developed by Rockwood et al. [
29], was used to evaluate the frailty of hemodialysis patients. CFS consists of nine levels, ranging from very healthy to terminally ill, and it is accompanied by pictures and text descriptions for rapid and accurate assessment. The CFS was scored from 9 to 1, with a higher score indicating better physical health. The scale is sensitive and specific for identifying the degree of frailty, with reported sensitivity and specificity values of 94.1% and 85.2%, respectively [
30,
31]. The CFS has also been correlated with mortality, comorbidity, length of hospitalization, falls, cognition, and physical functioning and has demonstrated a high predictive value for health outcomes in hospitalized patients [
20].
Data collection and analysis: Basic health information and the consent form were obtained before the commencement of hemodialysis, and further information was collected during the process with no delay in the participants' hemodialysis. Data were obtained through face-to-face structured interviews, considering the participants' hemodialysis needs from August 2021 to February 2022.
The data were analyzed with SPSS version 28 for Windows (IBM Corp., Armonk, NY, USA). A statistically significant P value was considered <.05. Descriptive statistics, including means, standard deviations, frequency distributions, and proportions, were used to summarize variables. Pearson’s correlation coefficient was calculated to determine the associations between variables, such as demographics between sarcopenia and healthy population, sarcopenia, and frailty. Linear and logistic regression analyses were used to investigate potential predictors of sarcopenia.
Ethical considerations: The National Science and Technology Council supported this study for Taiwanese undergraduate students’ research program (110-2813-C-255-016-B). The institutional review board (202101081B0) approved the study, and informed consent was obtained from all participants. This study was conducted in accordance with the principles of the Declaration of Helsinki.
3. Results
Participant characteristics and health information. Ninety-six hemodialysis patients participated in this study. This sample represented 82% of the population in the dialysis center. Reasons for non-participation included concerns about privacy, interference with the hemodialysis process, patient exhaustion, impaired awareness, dementia, and nonverbal condition (with tracheostomy).
Table 1 provides participants’ health information.
Differences in demographic characteristics between patients with sarcopenia and healthy population.Table 2 presents the differences in demographic characteristics between sarcopenia patients and the healthy population. Age (t= −5.41, p <.001) ), illiteracy (t= 9.50, p=.02), married (t= 6.07, p=.01), no children (t= 8.33, p=.04), body height (X2 =2.45, p=.02), body weight before (X2 =2.75, p=.01) and after (X2 =2.59, p=.01) dialysis, hand grip (X2 =5.82, p<.001), and left (X2 =4.02., p<.001) and right (X2 =3.52, p=.001) calf circumference were significantly different between sarcopenic patients and the healthy population. There is also a significant difference between sarcopenic patients and the healthy population in frailty (X2 =9.51, p <.001).
Correlation between sarcopenia and frailty. A higher frailty score and a lower sarcopenia score indicate a person with good health status. We found a strong negative correlation (r= −.853, p<.001) between sarcopenia and frailty, indicating that sarcopenia and frailty have a strong mutual influence. A moderate correlation between sarcopenia and frailty in sarcopenia patients (r= −.66, p<.001) and healthy populations also was found (r= −.58, p<.001) (
Table 3).
Logistic regression analysis of the risk of sarcopenia. Age and hand grip strength predict the risk of sarcopenia. The findings in
Table 4 indicate that an increase of one year in age significantly increases the risk of sarcopenia (OR 1.163, 95% CI=1.049, 1.288; p=.04). Each kilogram of hand grip strength affects the probability of having sarcopenia by 89.7% (OR 0.897, 95% CI=.807, .998; p=.046).
Predictors of sarcopenia and frailty in hemodialysis patients. Differences between sarcopenia and frailty in hemodialysis patients reached statistical significance in age, body weight before hemodialysis, and left calf circumference. Increased age resulted in an increased chance of the hemodialysis patients developing sarcopenia (ß=.096, p < .001) and a decreased possibility of developing frailty (ß=.049, p < .001). Increased body weight before dialysis indicated a high risk of sarcopenia in the SARC-F measure (ß=.083, p < .001) and a low risk of frailty in CFS (ß= −.032, p < .001). Furthermore, every kilogram in hand grip strength reduced the SARC-F score (ß= −.075, p = .012) and increased the CFS score (ß=.047, p < .001). This result identified hand grip strength as a potential predictor of sarcopenia and frailty. However, increased left calf circumference resulted in a lower SARC-F score (sarcopenia) (ß= −.128, p = .049) but an insignificant change in CFS score (frailty) (ß= .027, p = .332). These findings suggest that age, body weight before dialysis, hand grip strength, and calf circumference are essential factors in sarcopenia and frailty of hemodialysis patients (
Table 5).
4. Discussion
About one-third of hemodialysis patients were found to have sarcopenia and were a mean age of ten years older than the healthy population. Differences in hand grip strength and calf circumferences were statistically significant between those with vs. without sarcopenia. These results are consistent with the results of previous research on the relationship between aging and muscle loss [
32] and an increased risk of sarcopenia, as highlighted in previous studies by Ferrucci and Fabbri [
7] and Rosenberg [
15]. In addition, the occurrence of sarcopenia may be tracked back to the pathophysiology of chronic diseases. However, limited literature exists on the relationship between demographics, future studies should investigate these factors to understand the risk factors for sarcopenia better.
As determined from current research, sarcopenia is strongly associated with frailty, whether with or without sarcopenia. The results revealed that age is essential in developing sarcopenia and frailty, with senior individuals experiencing more significant physical weakness [
33]. However, participants were predominantly senior citizens. Therefore, it is unclear whether their sarcopenia and frailty are caused by age or their underlying CKD. Moreover, hand grip strength and left calf circumference can be predictors of sarcopenia, which can infer frailty among hemodialysis subjects. Knowing if the independent variable is sarcopenia or frailty would be valuable in managing the influences of these two conditions. Age, muscle mass, muscle strength, and several chronic diseases can be seen as a loop reaction between sarcopenia and frailty, which should be explored further.
This study revealed that hand grip strength could identify sarcopenia and frailty, and several studies support it. Escriche-Escuder et al. [
25] found a positive correlation between muscle mass in the lower limbs and muscle strength and a negative correlation with the risk of falling [
34]. Ito et al. [
35] documented that skeletal muscle mass is associated with bone mineral density in CKD dialysis patients' spinal cord and femoral head. While muscle mass is essential, Marini et al. [
28] emphasized that muscle strength, determined by walking, lifting chairs, climbing stairs, and falling (SARC-F), may provide more helpful information than muscle mass alone. These studies demonstrate that pathophysiological changes in CKD hemodialysis patients can decrease muscle mass and strength, significantly diminishing health and quality of life.
This study found no correlation between the length of hemodialysis and the incidence of sarcopenia, consistent with a recent study by Shu et al. [
36]. However, an older study by Takamoto et al. [
37] reported that longer hemodialysis duration was associated with a higher incidence of sarcopenia. The discrepancy between these findings may be attributed to differences in the hemodialysis duration among participants. Nevertheless, our study highlights the importance of maintaining the quality of hemodialysis to prevent sarcopenia and improve the overall health of hemodialysis patients.
Most hemodialysis people suffer from chronic diseases, often with two to four conditions overlapping, including high blood pressure, diabetes, and cardiovascular health problems. These three health problems also affect each other's health status, leading to the possibility of reducing skeletal muscle mass. Insulin resistance and poor glycemic control can minimize skeletal muscle mass and strength due to lipotoxicity, as demonstrated by Meex et al. [
38] and Joo et al. [
39]. Furthermore, smoking is associated with insulin resistance, indirectly affecting muscle mass and strength. Our study highlights the importance of managing chronic diseases and avoiding unhealthy lifestyle factors such as smoking to prevent sarcopenia and maintain muscle mass and strength in hemodialysis patients.
Study Limitations and Recommendations for further study. Limitations of this study should be considered when interpreting the results and future research directions. Firstly, the study design was cross-sectional, which may limit the ability to establish causality between sarcopenia, frailty, and hemodialysis. A longitudinal study design would provide a more comprehensive understanding of the development of sarcopenia and frailty among hemodialysis patients and facilitate the implementation of preventive measures. Secondly, the study sample was taken from a single organization only, which may limit the generalizability of the findings. A more extensive and diverse selection from multiple organizations would enhance the external validity of the results. Future studies may explore additional factors that contribute to the health outcomes of hemodialysis patients.
5. Conclusions
This study highlights the interrelationships between demographic and health-related factors and their impact on muscle mass and strength (sarcopenia) and frailty among hemodialysis people. Age and chronic diseases are the common factors influencing the incidence of sarcopenia and frailty. While age is an organic variable that cannot be controlled, chronic diseases can be prevented by adopting a healthy lifestyle and eating habits. Thus, the study recommends that health policies focus on health promotion and disease prevention to reduce the incidence of chronic diseases and comorbidities among hemodialysis people. Future research should explore the impact of chronic diseases and other factors, such as medication use, on the development of sarcopenia and frailty in this population. Additionally, an effective and comprehensive screening tool should be developed to assess frailty among the hemodialysis population, which can help in early detection and intervention to improve the quality of life.
Author Contributions
S-F Liu designed and organized the original study, data collection and analysis, and the study grant holder. C-C Lin was S-F Liu's study supervisor. C-C Lin worked with S-F Liu from the beginning of the study to design and organize the original study and data analysis and drafted the initial manuscript. S-L Hwang did the data analysis with the SPSS and provided recommendations for the data analysis process. C-Y Han contributed to the process of data collection and the final draft. Y-L Huang conducted quantitative data analysis and interpretation and proofreading. L-C Chen assisted in organizing the study site and approaching participants in the data collection process. All authors reviewed the manuscript.
Funding
This work was supported by the Ministry of Science and Technology (MOST) research grant for university students (110-2813-C-255-016-B), Taiwan. The funder did not involve in any stages of the study, study design, data collection and analysis, and manuscript writing.
Institutional Review Board Statement
This study was approved by the Chang Gung Medical Foundation Institutional Review Board (202101081B0) and conducted in accordance with accepted standards. Informed consent was obtained from all participants and their privacy was maintained. Any potential conflicts of interest have been disclosed.
Data Availability Statement
The data presented in this study are available from the corresponding author upon reasonable request.
Acknowledgments
The authors would like to appreciate the support from the Ministry of Science and Technology, Taiwan, and all participants involving this study. Especial thanks to the hospital's vice-director of the nursing department Shu-Nu Chen, for her assistance in approaching potential participants and getting entrance to the field. An appreciation also sends to Dr. Ping-Ru, Hsiao for her initial statistics guide.
Conflicts of Interest
The authors declare no conflict of interest.
References
- National Health Research Institutes & Taiwan Society of Nephrology. Kidney Disease in Taiwan-Annual Report, 2020.
- Yuhei, O.; Rhee, C.M.; Nguyen, M.; Kalantar-Zadeh, K.; Kopple, J.D. Current status of the assessment of sarcopenia, frailty, physical performance, and functional status in chronic kidney disease patients. Curr. Opin. Nephrol. Hypertens. 2022, 31, 109–128. [Google Scholar]
- Fried, L.P.; Darer, J.; Walston, J. Frailty 2003; In Geriatric medicine (pp. 1067-1076). Springer, New York, NY.
- Wang, Y.H.; Chiu, C.L.; Yang, C.L. Nutrition care for chronic kidney disease with sarcopenia. Clin. Med. (In Chinese). 2018, 82, 646–651. [Google Scholar]
- Daly, R.M.; Iuliano, S.; Fyfe, J.J.; Scott, D.; Kirk, B.; Thompson, M.Q.; et al. Screening, Diagnosis, and Management of Sarcopenia and Frailty in Hospitalized Older Adults: Recommendations from the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Expert Working Group. J. Nutr. Health Aging 2022, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Hoogendijk, E.O.; Afilalo, J.; Ensrud, K.E.; Kowal, P.; Onder, G.; Fried, L.P. Frailty: implications for clinical practice and public health. The Lancet 2019, 394, 1365–1375. [Google Scholar] [CrossRef] [PubMed]
- Ferrucci, L.; Fabbri, E. Inflammageing: chronic inflammation in aging, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 2018, 15, 505–522. [Google Scholar] [CrossRef] [PubMed]
- Veronese, N.; Siri, G.; Cella, A.; Magg, i.S.; Zigoura, E.; Puntoni, M.; et al. The multidimensional prognostic index predicts falls in older people: an 8-year longitudinal cohort study of the osteoarthritis initiative. J. Am. Med. Dir. Assoc. 2020, 21, 669–674. [Google Scholar] [CrossRef] [PubMed]
- Soysal, P.; Veronese, N.; Thompson, T.; Kahl, K.G.; Fernandes, B.S.; Prina, A.M.; et al. Relationship between depression and frailty in older adults: a systematic review and meta-analysis. Aging Res. Rev. 2017, 36, 78–87. [Google Scholar] [CrossRef] [PubMed]
- Kojima, G.; Iliffe, S.; Jivraj, S.; Walters, K. Association between frailty and quality of life among community-dwelling older people: a systematic review and meta-analysis. J. Epidemiol Community Health 2016, 70, 716–721. [Google Scholar] [CrossRef] [PubMed]
- Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; et al. Frailty in older adults: evidence for a phenotype. The Journals of Gerontology Series A: Biological Sciences and Medical Science 2001, 56, M146–M157. [Google Scholar] [CrossRef] [PubMed]
- Rockwood, K.; Mitnitski, A. Frailty in relation to the accumulation of deficits. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2007, 62, 722–727. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez-Mañas, L.; Féar, C.; Mann, G.; Viña, J.; Chatterji, S.; Chodzko-Zajko, W.; et al. Searching for an operational definition of frailty: a Delphi method based consensus statement. The frailty operative definition-consensus conference project. J. gerontol. ser. A-BiolMed. Sci. 2013, 68, 62–67. [Google Scholar] [CrossRef] [PubMed]
- Anani, S.; Goldhaber, G.; Brom, A.; Lasman, N.; Turpashvili, N.; Shenhav-Saltzman, G.; et al. Frailty and sarcopenia assessment upon hospital admission to internal medicine predicts length of hospital stay and re-admission: a prospective study of 980 patients. J. Clin. Med. 2020, 9, 2659. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, I.H. Sarcopenia: origins and clinical relevance. J. Nutr. 1997, 127, 990S–991S. [Google Scholar] [CrossRef] [PubMed]
- Beaudart, C.; Zaaria, M.; Pasleau, F.; Reginster, J. Y.; Bruyère, O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PloS One 2017, 12, e0169548. [Google Scholar] [CrossRef] [PubMed]
- Cruz-Jentoft, A.J.; Baha, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31. [Google Scholar] [CrossRef] [PubMed]
- Chen, U.P.; Kuo, Y.J.; Hun, g.S.W.; Wen, T.W.; Chien, P.C.; Chiang, M.H.; et al. Loss of skeletal muscle mass can be predicted by sarcopenia and reflects poor functional recovery at one year after surgery for geriatric hip fractures. Injury 2021, 5, 3446–3452. [Google Scholar] [CrossRef] [PubMed]
- Fielding, R.A.; Vellas, B.; Evans, W.J.; Bhasin, S.; Morley, J.E.; Newman, A.B.; et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J.Am. Med. Dir. Assoc. 2011, 12, 249–256. [Google Scholar]
- Church, S.; Rogers, E.; Rockwood, K.; Theou, O.A. Scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020, 20, 1–18. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.; Zhang, H.; Du, X.; Yin, L.; Zhang, H.; Zhou, Q. Comparison of the prevalence and associated factors of cognitive frailty between elderly and middle-young patients receiving maintenance hemodialysis. Int. Urol. Nephrol. 2022, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Gandolfini, I.; Regolisti, G.; Bazzocchi, A.; Maggiore, U.; Palmisano, A.; Piotti, G.; et al. Frailty and sarcopenia in older patients receiving kidney transplantation. Front. Nutr. 2019, 6, 169. [Google Scholar] [CrossRef]
- Hanach, N.I.; McCullough, F.; Avery, A. The impact of dairy protein intake on muscle mass, muscle strength, and physical performance in middle-aged to older adults with or without existing sarcopenia: A systematic review and meta-analysis. Adv. Nutr. 2019, 10, 59–69. [Google Scholar] [CrossRef] [PubMed]
- Santos, A.K.L.; Lima, T.L.; Costa, K.C.; Caetano, A.L.; Farias, E.H.C.; Silva, D.C.P.; et al. Serum Levels of Vitamin D and Parathyroid Hormone as Determinants of Sarcopenia in Patients with Chronic Renal Disease on Hemodialysis. Clin. J. Nutr. Diet 2020, 3, 1–7. [Google Scholar]
- Escriche-Escuder, A.; Fuentes-Abolafio, I.J.; Roldan-Jimenez, C.; Cuesta-Vargas, A.I. Effects of exercise on muscle mass, strength, and physical performance in older adults with sarcopenia: a systematic review and meta-analysis according to the EWGSOP criteria. Exp. Gerontol. 2021, 151, 111420. [Google Scholar] [CrossRef] [PubMed]
- Shiota, A.; Nakayama, N.; Saito, Y.; Maeda, T.; Maeda, Y.; Nakayama, K. Prevalence and Associated Factors of Malnutrition and Sarcopenia in a Daycare Facility: A Cross-Sectional Study. Healthcare 2020, 8, 576. [Google Scholar] [CrossRef] [PubMed]
- Malmstrom, T.K.; Morley, J.E. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J. Am. Med. Dir. Assoc. 2013, 14, 531–532. [Google Scholar] [CrossRef] [PubMed]
- Marini, A.C.B.; Perez, D.R.S.; Fleuri, J.A.; Pimentel, G.D. SARC-F is better correlated with muscle function indicators than muscle mass in older hemodialysis patients. J. Nutr. Health Aging 2020, 24, 999–1002. [Google Scholar] [CrossRef] [PubMed]
- Rockwood, K.; Song, X.; MacKnigh, t.C.; Bergman, H.; Hogan, D.B.; McDowell, I.; Mitnitski, A. A global clinical measure of fitness and frailty in elderly people. Can. Med. Assoc. J. 2005, 173, 489–495. [Google Scholar] [CrossRef] [PubMed]
- Liang, Y.D.; Zhang, Y.N.; Li, Y.M.; Chen, Y.H.; Xu, J.Y.; Liu, M.; et al. Identification of Frailty and Its Risk Factors in Elderly Hospitalized Patients from Different Wards: A Cross-Sectional Study in China. Clin. Interv. Aging 2019, 14, 2249–2259. [Google Scholar] [CrossRef] [PubMed]
- Ko, R.E.; Moon, S.M.; Kang, D.; Cho, J.; Chung, C.R.; Lee, Y.; et al. Translation and validation of the Korean version of the clinical frailty scale in older patients. BMC Geriatr. 2021, 21, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Ness, K.K.; Wogksch, M.D. Frailty and aging in cancer survivors. Transl. Res. 2020, 221, 65–82. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.J.; Son, Y. J. Prevalence and associated factors of frailty and mortality in patients with end-stage Renal disease undergoing hemodialysis: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health 2021, 18, 3471. [Google Scholar] [CrossRef] [PubMed]
- Rodrigues, F.; Domingos, C.; Monteiro, D.; Morouço, P. A review on aging, sarcopenia, falls, and resistance training in community-dwelling older adults. Int. J. Environ. Res. Public Health 2022, 19, 874. [Google Scholar] [CrossRef] [PubMed]
- Ito, K.; Ookawara, S.; Hibino, Y.; Imai, S.; Fueki, M.; Bandai, Y.; et al. Skeletal muscle mass index is positively associated with bone mineral density in hemodialysis patients. Front. Med. 2020, 7, 187. [Google Scholar] [CrossRef] [PubMed]
- Shu, X.; Lin, T.; Wang, H.; Zhao, Y.; Jiang, T.; Peng, X.; Yue, J. Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2022, 12890. [Google Scholar] [CrossRef] [PubMed]
- Takamoto, D.; Mochizuki, T.; Makiyama, K.; Teranishi, J.; Uemura, H. A Longer History of Hemodialysis Can Lead to Sarcopenia in Renal Transplantation Patients. Transplant. Proc. 2018, 50, 2447–2450. [Google Scholar] [CrossRef] [PubMed]
- Meex, R.C.; Blaak, E.E.; van Loon, L.J. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes. Rev. 2019, 20, 1205–1217. [Google Scholar] [CrossRef] [PubMed]
- Joo, K.C.; Son, D.H.; Park, J.K. Association between Relative Handgrip Strength and Insulin Resistance in Korean Elderly Men without Diabetes: Findings of the 2015 Korea National Health Nutrition Examination Survey. Korean J. Fam. Med. 2022, 43, 199. [Google Scholar] [CrossRef] [PubMed]
Table 1.
Demographic Characteristics (n=96).
Table 1.
Demographic Characteristics (n=96).
| |
Mean (SD)/n (%) |
|
Mean (SD)/n (%) |
| Age |
65.38 (SD11.52) |
Month of dialysis |
95.02(SD77.54) |
| Gender |
|
No. of dialysis per week |
|
| Men |
52 (54.2%) |
2 times |
3(3.1%) |
| Women |
44 (45.8%) |
3 times |
93(96.9%) |
| Educational level |
|
No. of hospitalized |
|
| Illiterate |
12 (12.5%) |
Never |
60 (62.5%) |
| Primary school |
27 (28.1%) |
Once |
29 (30.2%) |
| Middle/high school |
40 (41.6%) |
Two times |
4 (4.2%) |
| College and above |
17(17.7%) |
Three times and above |
3 (3.1%) |
| Marital status |
|
|
|
| Married |
66 (68.8%) |
|
|
| Single/divorced/ Widowed |
30 (31.2%) |
|
|
| No. of children |
|
Hand grip strength |
13.88 (SD8.61) |
| No |
21 (21.9%) |
Left calf circumference |
32.90(SD4.58) |
| 1–2 |
37(38.5%) |
Right calf circumference |
33.57(SD5.25) |
| 3–4 |
34(35.4%) |
Waist circumference |
91.46 (SD13.77) |
| ≥5 |
4(4.2%) |
|
|
| Body height |
160.83 (SD8.51) |
BMI |
24.85(SD5.15) |
| Body weight |
|
|
|
| Before dialysis |
64.69 (SD17.27) |
|
|
| After dialysis |
62.25(SD16.82) |
|
|
| No. of Chronic disease |
|
No. of cigarettes per day |
|
| 1 |
11 (11.5%) |
0–3 |
89 (92.7%) |
| 2 |
31 (32.3%) |
5–10 |
5 (5.2%) |
| 3 |
32 (33.3%) |
16 and above |
2 (2%) |
| 4 |
19 (19.8%) |
Betel nut per day |
|
| 5 |
2 (2.1%) |
Never |
95 (99%) |
| 6 |
1 (1%) |
Yes |
1 (1%) |
| Sleep Quality |
|
Alcohol consumption |
|
| Very dissatisfied |
5(5.2%) |
Never |
73(76%) |
| Dissatisfied |
18(18.8%) |
Quitted |
22(23%) |
| Neutral |
35(36.5%) |
Still drink |
1(1%) |
| Satisfied |
21(21.9%) |
|
|
| Very satisfied |
17(17.7%) |
|
|
| Comorbidities |
|
|
|
| Hypertension |
70 (72.9%) |
Hematology |
5 (5.2%) |
| Diabetes Mellitus |
38 (39.6%) |
Skin |
1 (1%) |
| Cardiovascular system |
34 (35.4%) |
Gastrointestinal system |
2 (2.1%) |
| Respiratory system |
5 (5.2%) |
Endocrine System |
2 (2.1%) |
| Cancer |
9 (9.4%) |
Urinary system |
30 (31.3%) |
| Stroke |
5 (5.2%) |
|
|
Table 2.
The Difference in Demographic Characteristics Between Sarcopenia and A Healthy Population.
Table 2.
The Difference in Demographic Characteristics Between Sarcopenia and A Healthy Population.
| Variables |
|
SARC_F |
| |
Healthy |
Sarcopenia |
t / X2 |
p |
| |
(Total scores = 0–4) |
(Total scores > 4) |
| |
n (%) |
n (%) |
|
Age (years) |
|
M (SD) |
61.33 (10.77) |
73.09 (8.71) |
−5.410*** |
<0.001 |
| Gender |
|
|
|
|
|
| |
Men |
|
38 (60.3) |
14 (42.4) |
2.793 |
0.095 |
| |
Women |
|
25 (39.7) |
19 (57.6) |
|
|
| Educational level |
|
|
|
|
|
| |
Illiterate |
|
7 (11.1) |
5 (15.2) |
9.502* |
0.023 |
| |
Primary school |
|
12 (19.0) |
15 (45.5) |
|
|
| |
Middle/high school |
|
32 (50.8) |
8 (24.2) |
|
|
| |
College and above |
|
12 (19.0) |
5 (15.2) |
|
|
| Marital status |
|
|
|
|
|
| |
Married |
|
38 (60.3) |
28 (84.8) |
6.066* |
0.014 |
| |
Single/divorced/ Widowed |
|
25 (39.7) |
5 (15.2) |
|
|
| No. of children |
|
|
|
|
|
| |
No |
|
19 (30.2) |
2 (6.1) |
8.326* |
0.040 |
| |
1–2 kids |
|
20 (31.7) |
17 (51.5) |
|
|
| |
3–4 kids |
|
21 (33.3) |
13 (39.4) |
|
|
| |
≥5 kids |
|
3 (4.8) |
1 (3.0) |
|
|
| Numbers of Chronic disease |
M (SD) |
2.62 (1.05) |
2.91 (1.01) |
−1.298 |
0.197 |
| Months of dialysis |
M (SD) |
95.86 (80.59) |
93.42 (72.55) |
0.145 |
0.885 |
| Times of dialysis per week |
|
|
|
|
|
| |
2 times |
|
2 (3.2) |
1 (3.0) |
0.001 |
0.969 |
| |
3 times |
|
61 (96.8) |
32 (97.0) |
|
|
| Hospitalized |
|
|
|
|
|
| |
Never |
|
40 (63.5) |
20 (60.6) |
0.077 |
0.781 |
| |
Yes |
|
23 (36.5) |
13 (39.4) |
|
|
| Times of hospitalized |
M (SD) |
0.41 (0.61) |
0.61 (0.90) |
−1.108 |
0.273 |
| Fall |
|
|
|
|
|
|
| |
Never |
|
50 (79.4) |
22 (66.7) |
1.862 |
0.172 |
| |
Yes |
|
13 (20.6) |
11 (33.3) |
|
|
| Times of fall |
M (SD) |
0.35 (0.81) |
0.61 (1.09) |
−1.311 |
0.193 |
| Times of surgery |
|
|
|
|
|
| |
1 time |
|
10 (15.9) |
2 (6.1) |
3.902 |
0.142 |
| |
2 times |
|
10 (15.9) |
10 (30.3) |
|
|
| |
> 2 times |
|
43 (68.3) |
21 (63.6) |
|
|
| Number of cigarettes per day |
M (SD) |
9.86 (6.26) |
10.00 |
−0.021 |
0.984 |
| Betel nut per day |
|
|
|
|
|
| |
Never |
|
50 (79.4) |
29 (87.9) |
3.831 |
0.147 |
| |
Quitted |
|
13 (20.6) |
3 (9.1) |
|
|
| |
Yes |
|
0 (0.0) |
1 (3.0) |
|
|
| Alcohol consumption |
|
|
|
|
|
| |
Never |
|
46 (73.0) |
27 (81.8) |
3.453 |
0.178 |
| |
Quitted |
|
17 (27.0) |
5 (15.2) |
|
|
| |
Still drink |
|
0 (0.0) |
1 (3.0) |
|
|
| Sleep Quality |
|
|
|
|
|
| |
Very dissatisfied |
|
2 (3.2) |
3 (9.1) |
5.776 |
0.216 |
| |
Dissatisfied |
|
9 (14.3) |
9 (27.3) |
|
|
| |
Neutral |
|
23 (36.5) |
12 (36.4) |
|
|
| |
Satisfied |
|
17 (27.0) |
4 (12.1) |
|
|
| |
Very satisfied |
|
12 (19.0) |
5 (15.2) |
|
|
|
Body height (cm) |
M (SD) |
162.33 (8.63) |
157.97 (7.61) |
2.449* |
0.016 |
|
Body weight (kg) |
|
|
|
|
|
| |
Before dialysis |
M (SD) |
67.47 (19.89) |
59.39 (8.67) |
2.762** |
0.007 |
| |
After dialysis |
M (SD) |
64.80 (19.41) |
57.39 (8.53) |
2.591* |
0.011 |
|
BMI (kg/m2) |
M (SD) |
25.35 (5.76) |
23.88 (3.62) |
1.332 |
0.186 |
|
Hand grip strength (kg) |
M (SD) |
16.79 (8.50) |
8.33 (5.65) |
5.823*** |
<0.001 |
|
Left calf circumference (cm) |
M (SD) |
34.13 (4.64) |
29.58 (6.32) |
4.018*** |
<0.001 |
|
Right calf circumference (cm) |
M (SD) |
34.59 (5.65) |
29.50 (8.45) |
3.516** |
0.001 |
|
Waist circumference (cm) |
M (SD) |
92.51 (15.20) |
89.47 (10.47) |
1.027 |
0.307 |
|
Hematocrit (%) |
M (SD) |
32.31 (4.29) |
33.12 (4.18) |
−0.886 |
0.378 |
|
Albumin (g/dL) |
M (SD) |
4.07 (0.29) |
4.73 (5.07) |
−0.744 |
0.462 |
|
Cholesterol (mg/dL) |
M (SD) |
153.52 (33.15) |
157.48 (38.93) |
−0.523 |
0.602 |
|
Triglycerides (mg/dL) |
M (SD) |
137.03 (89.71) |
135.79 (68.81) |
0.070 |
0.945 |
|
Blood Urea Nitrogen (mg/dL) |
M (SD) |
74.93 (17.13) |
68.67 (22.61) |
1.520 |
0.132 |
|
Creatinine (mg/dL) |
M (SD) |
11.73 (13.22) |
8.65 (1.81) |
1.328 |
0.187 |
|
The clinical frailty scale (scores) |
M (SD) |
6.86 (0.47) |
5.09 (1.01) |
9.509*** |
<0.001 |
Table 3.
Correlation Analysis Between Sarcopenia and Frailty.
Table 3.
Correlation Analysis Between Sarcopenia and Frailty.
| Sarcopenia |
Frailty |
| r |
p |
| SARC-F |
−0.853*** |
<0.001 |
| |
Muscle strength |
−0.582*** |
<0.001 |
| |
Walking |
−0.693*** |
<0.001 |
| |
Lifting chairs |
−0.620*** |
<0.001 |
| |
Climbing stairs |
−0.668 *** |
<0.001 |
| |
Falling |
−0.229* |
0.025 |
| SARC-F = 0–4 |
−0.578*** |
<0.001 |
| |
Muscle strength |
−0.233 |
0.066 |
| |
Walking |
−0.296* |
0.019 |
| |
Lifting chairs |
−0.133 |
0.300 |
| |
Climbing stairs |
−0.343** |
0.006 |
| |
Falling |
−0.197 |
0.122 |
| SARC-F > 4 |
−0.664*** |
<0.001 |
| |
Muscle strength |
−0.246 |
0.168 |
| |
Walking |
−0.483** |
0.004 |
| |
Lifting chairs |
−0.454** |
0.008 |
| |
Climbing stairs |
−0.303 |
0.087 |
| |
Falling |
−0.060 |
0.740 |
Table 4.
Logistic Regression Analysis of the Risk of Sarcopenia (n 96).
Table 4.
Logistic Regression Analysis of the Risk of Sarcopenia (n 96).
| Variables |
SARC-F |
| OR |
95% CI |
p |
|
Age (years) |
1.163** |
(1.049, 1.288) |
0.004 |
|
Educational levela
|
|
|
|
| Primary school |
3.067 |
(0.531, 17.728) |
0.211 |
| Middle/high school |
2.008 |
(0.257, 15.663) |
0.506 |
| College and above |
2.797 |
(0.229, 34.230) |
0.421 |
|
Marital status (Single/divorced/ Widowed) b
|
0.141 |
(0.014, 1.382) |
0.093 |
|
No. of children c
|
|
|
|
| 1–2 kids |
0.621 |
(0.036, 10.625) |
0.742 |
| 3–4 kids |
0.297 |
(0.013, 6.806) |
0.447 |
| ≥ 5 kids |
0.084 |
(0.001, 10.485) |
0.315 |
|
Body height (cm) |
0.953 |
(0.867, 1.048) |
0.323 |
|
Body weight before dialysis (kg) |
1.085 |
(0.996, 1.182) |
0.063 |
|
Hand grip strength (kg) |
0.897* |
(0.807, 0.998) |
0.046 |
|
Left calf circumference (cm) |
0.905 |
(0.681, 1.204) |
0.494 |
|
Right calf circumference (cm) |
0.921 |
(0.721, 1.175) |
0.507 |
Table 5.
Linear Regression Analysis of the Risk of Sarcopenia and Frailty.
Table 5.
Linear Regression Analysis of the Risk of Sarcopenia and Frailty.
| |
SARC-F |
|
CFS |
| Variables |
β |
95% CI |
p |
|
β |
95% CI |
p |
|
Age (years) |
0.096*** |
(0.047, 0.144) |
<0.001 |
|
−0.049*** |
(−0.070, −0.028) |
<0.001 |
|
Educational level a
|
|
|
|
|
|
|
|
| Primary school |
0.321 |
(−0.965, 1.606) |
0.621 |
|
0.054 |
(−0.505, 0.613) |
0.849 |
| Middle/high school |
−0.433 |
(−1.823, 0.957) |
0.537 |
|
0.000 |
(−0.605, 0.605) |
0.999 |
| College and above |
−0.730 |
(−2.337, 0.876) |
0.368 |
|
−0.204 |
(−0.903, 0.494) |
0.562 |
|
Marital status (Single/divorced/ Widowed) b
|
−0.937 |
(−2.202, 0.329) |
0.145 |
|
0.204 |
(−0.346, 0.754) |
0.463 |
|
No. of children c
|
|
|
|
|
|
|
|
| 1–2 kids |
−1.332 |
(−2.866, 0.201) |
0.088 |
|
0.260 |
(−0.407, 0.927) |
0.440 |
| 3–4 kids |
−1.811* |
(−3.468, −0.155) |
0.032 |
|
0.127 |
(−0.593, 0.848) |
0.726 |
| ≥ 5 kids |
−1.903 |
(−4.298, 0.492) |
0.118 |
|
0.492 |
(−0.550, 1.534) |
0.350 |
|
Body height (cm) |
−0.033 |
(−0.094, 0.027) |
0.278 |
|
0.010 |
(−0.016, 0.037) |
0.448 |
|
Body weight before dialysis (kg) |
0.083*** |
(0.045, 0.121) |
<0.001 |
|
−0.032* |
(−0.049, −0.016) |
<0.001 |
|
Hand grip strength (kg) |
−0.075* |
(−0.133, −0.017) |
0.012 |
|
0.047* |
(0.021, 0.072) |
<0.001 |
|
Left calf circumference (cm) |
−0.128* |
(−0.256, 0.000) |
0.049 |
|
0.027 |
(−0.028, 0.083) |
0.332 |
|
Right calf circumference (cm) |
−0.063 |
(−0.157, 0.032) |
0.190 |
|
0.025 |
(−0.016, 0.066) |
0.232 |
| Adjusted R-squared=0.440 |
|
Adjusted R-squared=0.474 |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).